L-DOPA NEW
| Price | $50 |
| Package | 200mg |
| Supply Ability: | 10g |
| Update Time: | 2025-11-08 |
Product Details
| Product Name: L-DOPA | CAS No.: 59-92-7 |
| Purity: 99.93% | Supply Ability: 10g |
| Release date: 2025/11/08 |
Product Introduction
Bioactivity
| Name | L-DOPA |
| Description | L-DOPA (Levodopa) is an orally active metabolic precursor of the neurotransmitter dopamine. It can cross the blood-brain barrier and be converted into dopamine in the brain. L-DOPA exhibits anti-hyperalgesic effects and holds potential in Parkinson’s disease research, and it can also be used to induce Parkinson’s disease models. |
| Kinase Assay | Briefly, transfected HEK-293 cells, incubated in charcoal-treated Dulbecco's modified Eagle's medium for 24 h, are washed once with Hanks' solution and resuspended in a buffer containing 100 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 250 mMsucrose, 20 mM Tris-HCl, pH 7.4. Cells are lysed by freezing in liquid nitrogen. Dehydrogenase activity is measured in a final volume of 20 μL containing the appropriate concentration of bile acid, 30 nCi of [3H]cortisol, and unlabeled cortisol to a final concentrations of 50 nM. The reaction is started by mixing cell lysate with the reaction mixture. Alternatively, endoplasmic reticulum microsomes are prepared from transfected HEK-293 cells and incubated with reaction mixture containing various concentrations of cortisol and CDCA. Incubation proceeded for 20 min, and the conversion of cortisol to cortisone is determined by thin layer chromatography (TLC). Because of the inaccuracy of the TLC method at low conversion rates and the end-product inhibition of 11βHSD2 at conversion rates higher than 60-70%, only conversion rates between 10 and 60% are considered for calculation. The inhibitory constant IC50 is evaluated using the curve-fitting program. Results are expressed as means±S.E. and consist of at least four independent measurements. |
| In vitro | Levodopa produces at 25-200 μM concentrations a dose-dependent reduction of 3H-DA uptake in foetal rat midbrain cultures. Levodopa results in a decrease in the number of viable cells and tyrosine hydroxylase (TH) positive neurones, plus disruption of the overall neuritic network. [1] Levodopa induces dyskinesia in the absence of dopamine by excessive inhibition of neurons of the putamen-globus pallidus (GPe) projection and subsequent disinhibition of the globus pallidus (GPe). Levodopa results in a decrease in cytochrome oxidase messenger RNA expression in the globus pallidus (GPi). [2] |
| In vivo | Levodopa elicits the development of a variety of abnormal movements in monkeys with parkinsonism induced by the neurotoxin MPTP. Levodopa administrations result in an ectopic induction of the dopamine D3receptor expression in the CdPu in 6-OHDA-lesioned rats. [3] Levodopa (50 mg/kg) increases anandamide concentrations throughout thebasal ganglia via activation of dopamine D1/D2 receptors in intact rats. Levodopa produces increasingly severe oro-lingual involuntary movements which are attenuated by the cannabinoid agonist R(+)-WIN55,212-2 (1 mg/kg) in lesioned rats. [4] Levodopa administration reverses the up-regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that Levodopa reaches a biologically active concentration at the basal ganglia. [5] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : Insoluble H2O : 2.5 mM, Sonication is recommended. |
| Keywords | precursor | Parkinson | Orally | neurotransmitters | L-DOPA | LDOPA | L DOPA | Inhibitor | inhibit | EndogenousMetabolite | Endogenous Metabolite | DopamineReceptor | Dopamine Receptor | dopamine | Dopamine | blood-brain | barrier | anti-allodynic |
| Inhibitors Related | Sucrose | Cysteamine hydrochloride | Acetaminophen | Daidzein | Fumaric acid | Guanidine hydrochloride | Ferulic Acid | Formamide | Glycerol | Thymidine | Naringin | 3-Indoleacetic acid |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-07 | ||
| $999.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-06-07 | |
|
VIP5Y
|
Sinoway Industrial co., ltd.
|
2026-06-03 | ||
|
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2026-06-02 | ||
|
VIP3Y
|
Hangzhou Hyper Chemicals Limited
|
2026-05-29 | ||
|
VIP3Y
|
BINBO BIOLOGICAL CO.,LTD
|
2026-05-22 | ||
| $210.00 |
VIP6Y
|
Baoji Guokang Healthchem Co., Ltd.
|
2026-05-15 | |
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
|
VIP4Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2026-01-04 | ||
|
VIP9Y
|
Guangzhou PI PI BIOTECH INC
|
2025-12-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY